{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:46:50Z","timestamp":1775749610844,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003819","name":"natural science foundation of hubei province","doi-asserted-by":"publisher","award":["2020CFB397"],"award-info":[{"award-number":["2020CFB397"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Independent Innovation Foundation of Wuhan Union Hospital","award":["2019-109"],"award-info":[{"award-number":["2019-109"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00520-021-06689-6","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T19:02:28Z","timestamp":1636830148000},"page":"2445-2453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies"],"prefix":"10.1007","volume":"30","author":[{"given":"Bo-Ya","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Xiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-7721","authenticated-orcid":false,"given":"Bi-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"6689_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2147\/cmar.S280995","volume":"13","author":"M Suehiro","year":"2021","unstructured":"Suehiro M, Kojima Y, Takahashi M, Ito Y, Keira T, Ikegawa K, Minatogawa H, Tsugawa K, Tanaka T (2021) Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and dexamethasone-sparing after day two for cancer patients receiving anthracycline and cyclophosphamide. Cancer Manag Res 13:1617\u20131624. https:\/\/doi.org\/10.2147\/cmar.S280995","journal-title":"Cancer Manag Res"},{"key":"6689_CR2","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1007\/s00520-019-04813-1","volume":"27","author":"H Kawazoe","year":"2019","unstructured":"Kawazoe H, Murakami A, Uozumi R, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y (2019) A four-drug combination of olanzapine, aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracy cline\u202f: a retrospective observational study. Support Care Cancer 27:S28. https:\/\/doi.org\/10.1007\/s00520-019-04813-1","journal-title":"Support Care Cancer"},{"key":"6689_CR3","doi-asserted-by":"publisher","first-page":"16232","DOI":"10.1038\/s41598-018-34618-x","volume":"8","author":"H Kawazoe","year":"2018","unstructured":"Kawazoe H, Uozumi R, Murakami A, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y (2018) Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: a retrospective study. Sci Rep 8:16232. https:\/\/doi.org\/10.1038\/s41598-018-34618-x","journal-title":"Sci Rep"},{"key":"6689_CR4","unstructured":"National Comprehensive Cancer Network (NCCN) (2020) Clinical practice guidelines in oncology. Antiemesis. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"6689_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 Updated MASCC\/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer 25:277\u2013288. https:\/\/doi.org\/10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"},{"key":"6689_CR6","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/jco.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K et al (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35:3240\u20133261. https:\/\/doi.org\/10.1200\/jco.2017.74.4789","journal-title":"J Clin Oncol"},{"key":"6689_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"6689_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL (2020) Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial. JAMA Oncol 6:895\u2013899. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1052","journal-title":"JAMA Oncol"},{"key":"6689_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663. https:\/\/doi.org\/10.1007\/s00520-012-1710-6","journal-title":"Support Care Cancer"},{"key":"6689_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14:141\u2013147. https:\/\/doi.org\/10.12788\/jcso.0245","journal-title":"J Community Support Oncol"},{"key":"6689_CR11","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392. https:\/\/doi.org\/10.1007\/s00520-016-3075-8","journal-title":"Support Care Cancer"},{"key":"6689_CR12","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29:3439\u20133459. https:\/\/doi.org\/10.1007\/s00520-020-05935-7","journal-title":"Support Care Cancer"},{"key":"6689_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 62:1006\u20131012. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005","journal-title":"J Clin Epidemiol."},{"key":"6689_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.2019.10517","volume":"322","author":"AJ Flint","year":"2019","unstructured":"Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Mulsant BH, Group S-PIS (2019) Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission: the STOP-PD II randomized clinical trial. JAMA. 322:622\u201331. https:\/\/doi.org\/10.1001\/jama.2019.10517","journal-title":"JAMA."},{"key":"6689_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.21037\/apm.2019.08.04","volume":"8","author":"P Tienchaiananda","year":"2019","unstructured":"Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S, Maneechavakajorn J (2019) A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Ann Palliat Med 8:372\u2013380. https:\/\/doi.org\/10.21037\/apm.2019.08.04","journal-title":"Ann Palliat Med"},{"key":"6689_CR16","doi-asserted-by":"publisher","unstructured":"Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, Gaipl US (2020) Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open 5. https:\/\/doi.org\/10.1136\/esmoopen-2019-000621","DOI":"10.1136\/esmoopen-2019-000621"},{"key":"6689_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249. https:\/\/doi.org\/10.1016\/s1470-2045(19)30678-3","journal-title":"Lancet Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06689-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T08:12:32Z","timestamp":1643271152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06689-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["6689"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06689-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have agreed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}